Lifevantage Corporation (NASDAQ:LFVN) saw stock price jump past 200-day moving average Thursday, hitting $10.50 before closing at $9.49. That average sits at $5.73. Trading volume hit 710,001 shares, showing market activity is heating up.
Analysts have been busy tweaking ratings for Lifevantage. On May 26,Weiss Ratings bumped it from “hold (c-)” to “hold (c)” . Lake Street Capital went other way,dropping it from “buy” to “hold” with $5.00 target price on May 7 . Consensus now? “Hold” with $5.00 average target.
Financial results are mixed. Company reported $0.12 per share for quarter ending May 6,missing $0.16 target. Revenue was $43.72 million,short of expected $47.77 million. Despite this,Lifevantage holds market cap of $119.76 million, with a P/E ratio of 21.09 and beta of 0.69.
Lifevantage announced quarterly dividend of $0.05, payable June 15 to shareholders on record as of June 1. This is up from previous $0.05,giving annualized yield of 2.1% and payout ratio of 44.44%.
Institutional investors are shuffling their stakes . In Q1,Cubist Systematic Strategies LLC picked up new stake worth about $97,000. Jones Financial Companies Lllp boosted holdings by 14,484%, now owning 29,168 shares valued at $425,000. Goldman Sachs Group Inc. increased its stake by 24.5%,holding 44,518 shares worth $649,000. Others like Jane Street Group LLC and Geode Capital Management LLC also upped their stakes to 36,567 and 245,332 shares,respectively.
Founded in 1999 and based in Sandy,Utah,Lifevantage deals in nutritional supplements,skincare, and weight-management products Its main product, Protandim®,aims to activate Nrf2 pathway,tied to cellular defense. Company also offers PhysIQ® for metabolism and body composition, and TrueScience® skincare.
